A large‐scale analysis of alternative splicing reveals a key role of QKI in lung cancer. Issue 9 (9th August 2016)

• Record Type: Journal Article
• Authors: de Miguel, Fernando J.; Pajares, María J.; Martínez-Terroba, Elena; Ajona, Daniel; Morales, Xabier; Sharma, Ravi D.; Pardo, Francisco J.; Rouzaut, Ana; Rubio, Angel; Montuenga, Luis M.; Pio, Ruben
• Is Part Of: Molecular oncology. Volume 10:Issue 9(2016:Nov.)
• Page Start: 1437
• Page End: 1449
• Publication Date: 2016-08-09
• Subjects: Alternative splicing -- Non‐small cell lung cancer -- ESYT2 -- QKI; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1016/j.molonc.2016.08.001
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Increasing interest has been devoted in recent years to the understanding of alternative splicing in cancer. In this study, we performed a genome‐wide analysis to identify cancer‐associated splice variants in non‐small cell lung cancer. We discovered and validated novel differences in the splicing of genes known to be relevant to lung cancer biology, such as NFIB, ENAH or SPAG9. Gene enrichment analyses revealed an important contribution of alternative splicing to cancer‐related molecular functions, especially those involved in cytoskeletal dynamics. Interestingly, a substantial fraction of the altered genes found in our analysis were targets of the protein quaking (QKI), pointing to this factor as one of the most relevant regulators of alternative splicing in non‐small cell lung cancer. We also found that ESYT2, one of the QKI targets, is involved in cytoskeletal organization. ESYT2‐short variant inhibition in lung cancer cells resulted in a cortical distribution of actin whereas inhibition of the long variant caused an increase of endocytosis, suggesting that the cancer‐associated splicing pattern of ESYT2 has a profound impact in the biology of cancer cells. Finally, we show that low nuclear QKI expression in non‐small cell lung cancer is an independent prognostic factor for disease‐free survival (HR = 2.47; 95% CI = 1.11–5.46, P = 0.026). In conclusion, we identified several splicing variants with functional relevance in lung cancer largely regulated by the splicing factor QKI, a tumor suppressor associated with prognosis in lung cancer. Highlights: We have generated an extensive list of differential splicing events in lung cancer. The splicing factor QKI is a major regulator of alternative splicing in lung cancer. The splicing of ESYT2, a QKI target, regulates actin and endocytosis dynamics. QKI protein downregulation is an independent factor for poor prognosis in lung cancer.